share_log

OTS---大幅続伸、S-588410第III相臨床試験結果論文の公表を引き続き好感

OTS - significant continued increase, favorable continued publication of the S-588410 Phase III clinical trial results paper.

Fisco Japan ·  Aug 1 00:48

Marked increase, reaching a new high for the year. On July 30th, the publication of the results paper for the S-588410 Phase III clinical trial targeting esophageal cancer patients was announced, and the company continues to be well received. The paper summarizes the results of the Phase III clinical trial targeting esophageal cancer patients for the S-588410 cancer-specific peptide vaccine licensed out to Shionogi & Co., Ltd., and is published in the journal Esophagus. The patent acquisition of a breast cancer treatment drug which includes a PHB2-derived peptide inhibiting the BIG3-PHB2 interaction is also being considered as a material.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment